Botox® (Botulinum Toxin Type A) was approved for medical use by the FDA in December 1989. Since then, it has become the treatment of choice for a number of movement disorders. These include such conditions as cervical dystonia, blepharospasm, hemifacial spasm and limb dystonia. All of these conditions are characterized by involuntary muscle contraction and twitching. Botox® helps to relieve symptoms by decreasing the treated muscles’ ability to contract. Other newer uses for Botox® have been tried over the past few years.